Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Saylor

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
European Urology|January 14, 2017
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital ExperienceNicholas J Giacalone, William U Shipley, Rebecca H Clayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor GenesCarla Calagua, Miriam Ficial, Caroline S Jansen, et al.
Cancer Cell|November 1, 2021
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironmentYoumna Kfoury, Ninib Baryawno, Nicolas Severe, et al.
JCO Precision Oncology|February 14, 2024
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate CancerPhilip J Saylor, Keisuke Otani, Rene Balza, et al.
Nature Communications|February 7, 2023
Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analysesTaghreed Hirz, Shenglin Mei, Hirak Sarkar, et al.
JCI Insight|February 15, 2024
Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signatureShenglin Mei, Adele M Alchahin, Bethel Tesfai Embaie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.
Genome Medicine|January 28, 2024
Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesionsShenglin Mei, Adele M Alchahin, Ioanna Tsea, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
The Lancet. Oncology|May 15, 2023
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysisAlexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
European Urology|January 14, 2017
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital ExperienceNicholas J Giacalone, William U Shipley, Rebecca H Clayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor GenesCarla Calagua, Miriam Ficial, Caroline S Jansen, et al.
Cancer Cell|November 1, 2021
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironmentYoumna Kfoury, Ninib Baryawno, Nicolas Severe, et al.
JCO Precision Oncology|February 14, 2024
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate CancerPhilip J Saylor, Keisuke Otani, Rene Balza, et al.
Nature Communications|February 7, 2023
Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analysesTaghreed Hirz, Shenglin Mei, Hirak Sarkar, et al.
JCI Insight|February 15, 2024
Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signatureShenglin Mei, Adele M Alchahin, Bethel Tesfai Embaie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.
Genome Medicine|January 28, 2024
Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesionsShenglin Mei, Adele M Alchahin, Ioanna Tsea, et al.
International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
The Lancet. Oncology|May 15, 2023
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysisAlexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, et al.
Pageof 5